Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE SURE bimekizumab in moderate to severe plaque psoriasis phase 3 trial

被引：0
|
作者：
Warren, Richard B. [1 ]
Augustin, Matthias [2 ]
Gottlieb, Alice B. [3 ]
Duffin, Kristina Callis [4 ]
Ciaravino, Valerie [5 ]
Cioffi, Christopher [6 ]
Peterson, Luke [6 ]
Blauvelt, Andrew [7 ]
机构：
[1] Univ Manchester, Dermatol Ctr, Salford Royal NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
[2] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Univ Utah, Dept Dermatol, Salt Lake City, UT USA
[5] UCB Pharma, Colombes, France
[6] UCB Pharma, Raleigh, NC USA
[7] Oregon Med Res Ctr, Portland, OR USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27373
引用
收藏
页码：AB138 / AB138
页数：1
相关论文
共 50 条
  • [31] Maintenance of Efficacy Results from UNCOVER-1: A Phase 3 Trial of Ixekizumab for Moderate-to-Severe Plaque Psoriasis
    Leonardi, C.
    Leutz, A.
    Blauvelt, A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Cameron, G. S.
    Erickson, J.
    Zhao, F.
    Shrom, D. S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Gordon, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
  • [32] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
    Leonardi, Craig
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Zhao, Fangyi
    Shrorn, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Gordon, Kenneth
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
  • [33] Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials
    Strober, Bruce
    Warren, Richard B.
    Foley, Peter
    Gooderham, Melinda
    Thaci, Diamant
    Cullen, Eva
    Cioffi, Christopher
    Peterson, Luke
    Madden, Cynthia
    Armstrong, April
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB76 - AB76
  • [34] Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial
    Augustin, Matthias
    Langley, Richard G.
    Warren, Richard B.
    Lebwohl, Mark
    Elewski, Boni
    Crowley, Jeffrey
    Warham, Rhys
    Kaspar, Markus
    Wiegratz, Susanne
    Ciaravino, Valerie
    Gottlieb, Alice B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB184 - AB184
  • [35] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial
    Kern, Johannes S.
    Feldman, Steven R.
    Gottlieb, Alice B.
    Soung, Jennifer
    Augustin, Matthias
    Gisondi, Paolo
    Peterson, Luke
    Vanvoorden, Veerle
    Ciaravino, Valerie
    Gomez, Natalie Nunez
    Warren, Richard B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 19
  • [36] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
    Feldman, Steven R.
    Gottlieb, Alice B.
    Soung, Jennifer
    Augustin, Matthias
    Gisondi, Paolo
    Peterson, Luke
    Vanvoorden, Veerle
    Ciaravino, Valerie
    Gomez, Natalie Nunez
    Warren, Richard B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
  • [37] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
    Lebwohl, Mark
    Ghoreschi, Kamran
    Strober, Bruce
    Eyerich, Kilian
    Cather, Jennifer
    Wang, Maggie
    Cioffi, Christopher
    Deherder, Delphine
    Staelens, Fabienne
    Gomez, Natalie Nunez
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
  • [38] Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial
    Shumack, Stephen
    Blauvelt, Andrew
    Iversen, Lars
    McBride, Sandy
    Gooderham, Melinda
    Staubach-Renz, Petra
    Yamauchi, Paul
    Staelens, Fabienne
    Vanvoorden, Veerle
    White, Katy
    Gisondi, Paolo
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 17 - 18
  • [39] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Spelman, Lynda
    Eyerich, Kilian
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 14
  • [40] Bimekizumab response maintenance in high-impact areas in patients with moderate to severe plaque psoriasis: Pooled results through 96 weeks of the BE SURE, BE READY, and BE RADIANT phase 3/3b trials
    Merola, Joseph F.
    Warren, Richard B.
    Han, George
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB24 - AB24
12345